A Phase 3 interventional study of Panitumumab and FOLFOX regimen in Metastatic Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-07.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 3rd largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2006, is one of 14 in phase 3, and was the 12th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
R-Pharm · Sites in Russia
Ages 18+
UNICANCER · Sites in France
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 68 · Phase 3 15 · Phase 4 1
First in 2000; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,183 is above the median of 76 across 4,802 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 70 across the 88 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 90 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Colorectal Neoplasms by Amgen: 2 open now, 2 under way, 1 of them phase 3. Of 38 finished, 24 (63%) have results posted.
Among the 40 studies in Colorectal Neoplasms by Amgen, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2006, is one of 10 in phase 3, and was the 12th registered.
Amgen’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing panitumumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03087071M.D. Anderson Cancer CenterPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | 2027-01-31 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, from their registry updates:
Among Amgen’s 40 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the treatment effect of panitumumab in combination with FOLFOX compared to FOLFOX alone as first line therapy for metastatic colorectal cancer
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
Drug: Panitumumab · Drug: FOLFOX regimen
Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Drug: FOLFOX regimen
Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
Also known as: Vectibix®
The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
Progression-free Survival
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.
Time frame: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
Overall Survival
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date.
Time frame: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
Percentage of Participants With an Objective Response
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.
Time frame: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
Time to Progression
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria.
Time frame: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
Duration of Response
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review.
Time frame: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
Number of Participants With Adverse Events (AEs)
A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the study treatment?"
Time frame: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
First patient enrolled 23 August 2006 and last patient enrolled 01 February 2008. Participant flow data are reported as of the data cut-off date of 28 August 2009.
| Milestone | FOLFOX + Panitumumab | FOLFOX Alone |
|---|---|---|
| Started | 593 | 590 |
| Received study drug | 586 | 583 |
| Completed | 492 | 495 |
| Not completed | 101 | 95 |
| Withdrew: Ineligibility determined | 4 | 2 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Withdrawal by subject | 13 | 18 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Lost to follow-up | 10 | 3 |
| Withdrew: Protocol-specified criteria | 6 | 6 |
| Withdrew: Other | 41 | 47 |
| Withdrew: Ongoing | 20 | 13 |
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.
| months | Wild-type KRAS - FOLFOX + Panitumumab | Wild-type KRAS - FOLFOX | Mutant KRAS - FOLFOX + Panitumumab | Mutant KRAS - FOLFOX |
|---|---|---|---|---|
| Progression-free Survival | 9.6 (9.2 to 11.1) | 8.0 (7.5 to 9.3) | 7.3 (6.3 to 8.0) | 8.8 (7.7 to 9.4) |
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date.
| months | Wild-type KRAS - FOLFOX + Panitumumab | Wild-type KRAS - FOLFOX | Mutant KRAS - FOLFOX + Panitumumab | Mutant KRAS - FOLFOX |
|---|---|---|---|---|
| Overall Survival | 23.9 (20.3 to 28.3) | 19.7 (17.6 to 22.6) | 15.5 (13.1 to 17.6) | 19.3 (16.5 to 21.8) |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.
| percentage of participants | Wild-type KRAS - FOLFOX + Panitumumab | Wild-type KRAS - FOLFOX | Mutant KRAS - FOLFOX + Panitumumab | Mutant KRAS - FOLFOX |
|---|---|---|---|---|
| Percentage of Participants With an Objective Response | 55.21 (49.55 to 60.77) | 47.68 (42.12 to 53.28) | 39.53 (32.95 to 46.41) | 40.28 (33.61 to 47.24) |
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria.
| months | Wild-type KRAS - FOLFOX + Panitumumab | Wild-type KRAS - FOLFOX | Mutant KRAS - FOLFOX + Panitumumab | Mutant KRAS - FOLFOX |
|---|---|---|---|---|
| Time to Progression | 10.8 (9.4 to 12.4) | 9.2 (7.7 to 9.9) | 7.5 (7.2 to 8.9) | 9.0 (7.7 to 9.5) |
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review.
| months | Wild-type KRAS - FOLFOX + Panitumumab | Wild-type KRAS - FOLFOX | Mutant KRAS - FOLFOX + Panitumumab | Mutant KRAS - FOLFOX |
|---|---|---|---|---|
| Duration of Response | 11.1 (9.5 to 13.0) | 8.8 (7.8 to 9.7) | 7.4 (5.9 to 8.3) | 8.0 (6.5 to 9.5) |
A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the study treatment?"
| participants | FOLFOX + Panitumumab | FOLFOX Alone |
|---|---|---|
| Any adverse event | 583 | 579 |
| Serious adverse event | 262 | 198 |
| Leading to discontinuation of any study drug | 136 | 84 |
| Treatment-related adverse event (TRAE) | 581 | 565 |
| Serious treatment-related adverse event | 162 | 89 |
| TRAE leading to discontinuation of any study drug | 117 | 63 |
Collected over The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab Plus FOLFOX | — | 262/585 (44.8%) | 577/585 (98.6%) |
| FOLFOX Alone | — | 198/584 (33.9%) | 571/584 (97.8%) |
| Event | Panitumumab Plus FOLFOX | FOLFOX Alone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 58/585 | 17/584 |
| DehydrationMetabolism and nutrition disorders | 20/585 | 5/584 |
| Intestinal obstructionGastrointestinal disorders | 18/585 | 12/584 |
| VomitingGastrointestinal disorders | 18/585 | 12/584 |
| PyrexiaGeneral disorders | 16/585 | 15/584 |
| Febrile neutropeniaBlood and lymphatic system disorders | 15/585 | 14/584 |
| Abdominal painGastrointestinal disorders | 14/585 | 10/584 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 14/585 | 10/584 |
| NauseaGastrointestinal disorders | 12/585 | 3/584 |
| SepsisInfections and infestations | 12/585 | 7/584 |
| Event | Panitumumab Plus FOLFOX | FOLFOX Alone |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 315/585 | 353/584 |
| DiarrhoeaGastrointestinal disorders | 349/585 | 282/584 |
| RashSkin and subcutaneous tissue disorders | 305/585 | 39/584 |
| NauseaGastrointestinal disorders | 261/585 | 287/584 |
| ParaesthesiaNervous system disorders | 180/585 | 204/584 |
| FatigueGeneral disorders | 199/585 | 197/584 |
| AnorexiaMetabolism and nutrition disorders | 199/585 | 133/584 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 188/585 | 2/584 |
| VomitingGastrointestinal disorders | 175/585 | 182/584 |
| HypomagnesaemiaMetabolism and nutrition disorders | 175/585 | 39/584 |
| Age, Continuous(years) | FOLFOX + Panitumumab | FOLFOX Alone | Total |
|---|---|---|---|
| Mean | 61.5 ± 10.1 | 60.3 ± 11.0 | 60.9 ± 10.6 |
| Sex: Female, Male(Participants) | FOLFOX + Panitumumab | FOLFOX Alone | Total |
|---|---|---|---|
| Female | 207 | 232 | 439 |
| Male | 386 | 358 | 744 |
| Race/Ethnicity, Customized(participants) | FOLFOX + Panitumumab | FOLFOX Alone | Total |
|---|---|---|---|
| White or Caucasian | 530 | 540 | 1070 |
| Black or African American | 8 | 15 | 23 |
| Hispanic or Latino | 42 | 26 | 68 |
| Asian | 8 | 4 | 12 |
| Other | 5 | 5 | 10 |
| Geographic Region(participants) | FOLFOX + Panitumumab | FOLFOX Alone | Total |
|---|---|---|---|
| Western Europe, Canada and Australia | 332 | 329 | 661 |
| Rest of world | 261 | 261 | 522 |
| KRAS Status(participants) | FOLFOX + Panitumumab | FOLFOX Alone | Total |
|---|---|---|---|
| Wild-type KRAS | 325 | 331 | 656 |
| Mutant KRAS | 221 | 219 | 440 |
| Unevaluable KRAS | 47 | 40 | 87 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | FOLFOX + Panitumumab | FOLFOX Alone | Total |
|---|---|---|---|
| Grade 0 | 332 | 320 | 652 |
| Grade 1 | 230 | 238 | 468 |
| Grade 2 | 31 | 29 | 60 |
| Grade 3 | 0 | 0 | 0 |
| Grade 4 | 0 | 1 | 1 |
| Mising/Unknown | 0 | 2 | 2 |
| Primary tumor type(participants) | FOLFOX + Panitumumab | FOLFOX Alone | Total |
|---|---|---|---|
| Colon cancer | 394 | 398 | 792 |
| Rectal cancer | 199 | 192 | 391 |
No study locations are listed for this record.
Ran from Aug 2006 to primary completion in Aug 2009, 36 months.
Results were first posted in Mar 2014, 4 years 7 months after primary completion. A results delay was requested in Jul 2010.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 36 months is below that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab